Skip to main content

Canadian vaccine yields promising early results

Share
TORONTO -

The University of Saskatchewan’s Vaccine and Infectious Disease Organization (VIDO) has announced positive early results from phase one trials of its COVID-19 vaccine candidate: COVAC-2.

The results from the study show that the vaccine appears to be safe and “well tolerated,” according to a press release.

The study, conducted by Canadian Centre for Vaccinology (CCfV), said that the most commonly reported side effects among those who received the vaccine were headaches and mild pain at the injection site.

The study found that, even with low doses of the vaccine, there was enough of an antibody response to provide protection against COVID-19, according to the press release.

“The data continues to demonstrate the safety of our subunit vaccine COVAC-2. We are encouraged by the vaccine’s ability to generate a significant immune response, even at the lowest dose tested,” Dr. Volker Gerdts, director and CEO of VIDO, said in the release.

The COVAC-2 vaccine is a subunit vaccine, meaning it contains “purified viral proteins” that are not infectious.

CTVNews.ca Top Stories

New weight-loss drug Wegovy not a 'magic bullet,' doctor warns

As Wegovy becomes available to Canadians starting Monday, a medical expert is cautioning patients wanting to use the drug to lose weight that no medication is a ''magic bullet,' and the new medication is meant particularly for people who meet certain criteria related to obesity and weight.

Drew Carey is never quitting 'The Price Is Right'

Drew Carey took over as host of 'The Price Is Right' and hopes he’s there for life. 'I'm not going anywhere,' he told 'Entertainment Tonight' of the job he took over from longtime host Bob Barker in 2007.

Local Spotlight

Stay Connected